Chiral Synthesis of Carbocyclic Analogues of l-ribofuranosides
Chiral Synthesis of Carbocyclic Analogues of l-ribofuranosides
复制标题
L-呋喃核苷碳环类似物的手性合成
DOI:
10.1021/jo9812330
复制
发表时间:
1999
影响因子:
3.6
通讯作者:
C. K. Chu
中科院分区:
文献类型:
--
作者:
Peiyuan Wang;L. Agrofoglio;Andrew Newton;C. K. Chu
Natural products, D-(-)-aristeromycin and neplanocin A, are representatives of biologically interesting carbocyclic nucleosides. Natural as well as synthetic carbocyclic nucleosides1, 2 have shown interesting antitumor3 and antiviral activities against cytomegalovirus, 4 herpes virus, 5 hepatitis B virus, 6 and human immunodeficiency virus (HIV). 7, 8 Carbocyclic nucleosides possess an increased metabolic stability against nucleoside phosphorylases9 because of the absence of a true glycosidic bond. Among them, carbovir7 and 6-cyclopropylaminopurine analogue, 1592U89 (Abacavir), 10 are the most interesting compounds due to their potent anti-HIV activities. 1592 (Abacavir) has recently been approved by the FDA. Recently, a novel carbocyclic nucleoside, BMS-200475, has been reported to exhibit potent anti-HBV activity, and it is currently undergoing phase II clinical trials. 11 In recent years, a number of L-nucleosides, including (-)-(2′ R, 5′ S)-1-(2-hydroxymethyloxathiolan-5-yl) cytosine (3TC), 12, 13 (-)--L-2′, 3′-dideoxy-5-fluoro-3′-thiacytidine (FTC), 14-L-2′, 3′-dideoxy-5-fluorocytidine (L-FddC), 15, 16 and-L-2′-fluoro-5-methylarabinofuranosyl uracil (L-FMAU) 17 have shown promising antiviral activity. Both L-nucleosides, 3TC and FTC, exhibit more potent antiviral activity against HIV and hepatitis B virus (HBV) and decreased toxicity in comparison to their D-counterparts. 13, 18 Therefore, it was of interest to synthesize the corresponding L-carbocyclic nucleosides in anticipation of interesting antiviral activity. We have previously reported a preliminary account of L-cyclopentyl carbocyclic nucleoside. 19 In this paper, we report the experimental details, X-ray structure, and confirmation of L-cyclopentyl carbocyclic ribonucleosides.